AR030551A1 - Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante - Google Patents
Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultanteInfo
- Publication number
- AR030551A1 AR030551A1 ARP010100761A ARP010100761A AR030551A1 AR 030551 A1 AR030551 A1 AR 030551A1 AR P010100761 A ARP010100761 A AR P010100761A AR P010100761 A ARP010100761 A AR P010100761A AR 030551 A1 AR030551 A1 AR 030551A1
- Authority
- AR
- Argentina
- Prior art keywords
- nefiracetam
- composition
- neurodegeneration
- manufacture
- processing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
Uso de N-(-2,6-dimetilfenil)-2-(2-oxo-1-pirrolidinil) acetamida (nefiracetam) para la preparacion de medicamentos, particularmente de composiciones farmacéuticas que lo contienen como ingrediente activo, para el tratamiento de la neurodegeneracion, en particular en pacientes humanos después de un ataque cerebral. La administracion temprana de nefiracetam en dichas composiciones farmacéuticas después de un ataque cerebral permite una mejora en las Actividades del Diario Vivir y en la recuperacion, o al menos en la mejora de la recuperacion de pacientes después del ataque cerebral. Composicion farmacéutica que comprende una cantidad farmacologicamente efectiva de nefiracetam, como ingrediente activo y un vehículo farmacéuticamente aceptable. La composicion se presenta en una dosis unitaria de administracion oral, particularmente que contiene entre 50 y 1200 mg de nefiracetam.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51195200A | 2000-02-23 | 2000-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030551A1 true AR030551A1 (es) | 2003-08-27 |
Family
ID=24037094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010100761A AR030551A1 (es) | 2000-02-23 | 2001-02-21 | Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6423739B1 (es) |
| EP (1) | EP1171123B1 (es) |
| JP (1) | JP2003523385A (es) |
| KR (1) | KR20010110798A (es) |
| CN (1) | CN1362877A (es) |
| AR (1) | AR030551A1 (es) |
| AT (1) | ATE336246T1 (es) |
| AU (1) | AU784418B2 (es) |
| BR (1) | BR0104586A (es) |
| CA (1) | CA2368352C (es) |
| DE (1) | DE60122252T2 (es) |
| DK (1) | DK1171123T3 (es) |
| ES (1) | ES2270981T3 (es) |
| HK (1) | HK1047038A1 (es) |
| ID (1) | ID30377A (es) |
| IL (1) | IL145799A (es) |
| MX (1) | MXPA01010749A (es) |
| NO (1) | NO321911B1 (es) |
| TW (1) | TWI289060B (es) |
| WO (1) | WO2001062246A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077709A1 (en) * | 1999-05-31 | 2004-04-22 | Daiichi Pharmaceutical Co., Ltd. | Neuronal death inhibitors |
| DE60138733D1 (de) * | 2000-12-28 | 2009-06-25 | Hamilton Pharmaceuticals Inc | Arzneimittel zur behandlung und vermeidung neurogener schmerzen |
| WO2003018005A1 (en) * | 2001-08-22 | 2003-03-06 | Daiichi Pharmaceutical Co., Ltd. | use of nefiracetam for treating neurodegeneration |
| US20060241144A1 (en) * | 2005-04-20 | 2006-10-26 | Albert Cha | Method for treating apathy syndrome |
| WO2011048208A1 (en) | 2009-10-22 | 2011-04-28 | University College Dublin, National University Of Ireland, Dublin | Causal therapy of diseases or conditions associated with cns or pns demyelination |
| RU2480214C1 (ru) * | 2011-09-22 | 2013-04-27 | Валентина Ивановна Ахапкина | Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2469995A (en) * | 1946-07-23 | 1949-05-10 | Schaul Martin Carl | Process for the production of food preparations from potatoes and similar farinaceoustubers |
| US3031314A (en) * | 1960-03-16 | 1962-04-24 | Carl E Hendel | Preparation of dehydrated potatoes |
| US3260607A (en) * | 1961-02-07 | 1966-07-12 | Canadian Patents Dev | Preparation of dehydrated cooked mashed potato |
| US3968265A (en) * | 1973-02-01 | 1976-07-06 | American Potato Company | Freeze-thaw stable, french fry potato product and process for producing the same |
| IT1141287B (it) | 1979-06-13 | 1986-10-01 | Nattermann A & Cie | Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono |
| DE2924011C2 (de) | 1979-06-13 | 1982-04-08 | A. Nattermann & Cie GmbH, 5000 Köln | Pyrrolidin-(2)-on-(1)-ylessigsäure-2,6,-dimethylanilid, Verfahren zur Herstellung und Arzneimittel, welche diese Verbindung enthalten |
| DE2923975A1 (de) | 1979-06-13 | 1980-12-18 | Nattermann A & Cie | Pyrrolidinone, verfahren zu deren herstellung und diese enthaltende arzneimittel |
| CA2067614C (en) | 1991-05-02 | 2002-07-30 | Eiichi Otomo | Agent for improving dementia |
| US5525058A (en) | 1992-03-27 | 1996-06-11 | American Dental Technologies, Inc. | Dental treatment system |
| DE69519635T2 (de) | 1995-07-10 | 2001-05-31 | Kodera Electronics Co | Vorrichtung zum einbringen eines zu bearbeitenden drahtes |
| US6107330A (en) | 1995-08-07 | 2000-08-22 | Daiichi Pharmaceutical Co., Ltd. | Inhibitor for narcotic analgesic dependence/resistance acquisition |
| JP2002241272A (ja) | 1996-07-18 | 2002-08-28 | Mitsubishi Pharma Corp | 医薬処方組成物 |
| US6042818A (en) | 1996-07-30 | 2000-03-28 | Henkel Ecolab Gmbh & Co. Ohg | Film-building agent useful to protect against infections |
| EP0953356A4 (en) | 1996-10-01 | 2002-04-17 | Daiichi Seiyaku Co | MITOCHONDRIAL MEMBRANE STABILIZER |
| US6211701B1 (en) | 1996-12-16 | 2001-04-03 | Rose Research, Llc | Low power line switching circuit, device and method |
| IT1293533B1 (it) | 1997-07-14 | 1999-03-01 | Angeletti P Ist Richerche Bio | Metodo per la selezione di molecole in grado di mimare, inibire o potenziare gli effetti della interazione tra leptina e cellule che |
| CN1264301A (zh) | 1997-07-15 | 2000-08-23 | 第一制药株式会社 | 遗忘症的预防、治疗药 |
| JPH1180027A (ja) | 1997-09-12 | 1999-03-23 | Dai Ichi Seiyaku Co Ltd | 向知性薬 |
| TW544311B (en) | 1998-08-06 | 2003-08-01 | Daiichi Seiyaku Co | Therapeutic or preventive agent for intractable epilepsies |
| EP1180366A1 (en) | 1999-05-31 | 2002-02-20 | Daiichi Pharmaceutical Co., Ltd. | Neuronal death inhibitors |
-
2001
- 2001-02-16 US US09/784,048 patent/US6423739B1/en not_active Expired - Fee Related
- 2001-02-21 AR ARP010100761A patent/AR030551A1/es unknown
- 2001-02-23 JP JP2001561312A patent/JP2003523385A/ja active Pending
- 2001-02-23 WO PCT/JP2001/001342 patent/WO2001062246A1/en active IP Right Grant
- 2001-02-23 ES ES01906242T patent/ES2270981T3/es not_active Expired - Lifetime
- 2001-02-23 AU AU34145/01A patent/AU784418B2/en not_active Ceased
- 2001-02-23 IL IL145799A patent/IL145799A/en not_active IP Right Cessation
- 2001-02-23 BR BR0104586-5A patent/BR0104586A/pt not_active Application Discontinuation
- 2001-02-23 DK DK01906242T patent/DK1171123T3/da active
- 2001-02-23 KR KR1020017013542A patent/KR20010110798A/ko active Search and Examination
- 2001-02-23 CA CA002368352A patent/CA2368352C/en not_active Expired - Fee Related
- 2001-02-23 MX MXPA01010749A patent/MXPA01010749A/es active IP Right Grant
- 2001-02-23 DE DE60122252T patent/DE60122252T2/de not_active Expired - Lifetime
- 2001-02-23 EP EP01906242A patent/EP1171123B1/en not_active Expired - Lifetime
- 2001-02-23 ID IDW00200102283A patent/ID30377A/id unknown
- 2001-02-23 AT AT01906242T patent/ATE336246T1/de not_active IP Right Cessation
- 2001-02-23 TW TW090104150A patent/TWI289060B/zh not_active IP Right Cessation
- 2001-02-23 CN CN01800298A patent/CN1362877A/zh active Pending
- 2001-07-17 US US09/906,077 patent/US6399650B2/en not_active Expired - Fee Related
- 2001-10-22 NO NO20015162A patent/NO321911B1/no unknown
-
2002
- 2002-11-28 HK HK02108589.8A patent/HK1047038A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60122252D1 (de) | 2006-09-28 |
| US6399650B2 (en) | 2002-06-04 |
| CA2368352A1 (en) | 2001-08-30 |
| KR20010110798A (ko) | 2001-12-13 |
| NO20015162D0 (no) | 2001-10-22 |
| EP1171123B1 (en) | 2006-08-16 |
| DK1171123T3 (da) | 2006-12-04 |
| ES2270981T3 (es) | 2007-04-16 |
| CA2368352C (en) | 2009-11-10 |
| DE60122252T2 (de) | 2007-07-05 |
| HK1047038A1 (zh) | 2003-02-07 |
| NO321911B1 (no) | 2006-07-17 |
| CN1362877A (zh) | 2002-08-07 |
| JP2003523385A (ja) | 2003-08-05 |
| EP1171123A1 (en) | 2002-01-16 |
| BR0104586A (pt) | 2002-01-08 |
| AU784418B2 (en) | 2006-03-30 |
| ID30377A (id) | 2001-11-29 |
| TWI289060B (en) | 2007-11-01 |
| US20010051653A1 (en) | 2001-12-13 |
| AU3414501A (en) | 2001-09-03 |
| US20020055534A1 (en) | 2002-05-09 |
| IL145799A0 (en) | 2002-07-25 |
| NO20015162L (no) | 2001-12-21 |
| IL145799A (en) | 2006-10-31 |
| MXPA01010749A (es) | 2002-08-20 |
| US6423739B1 (en) | 2002-07-23 |
| ATE336246T1 (de) | 2006-09-15 |
| WO2001062246A1 (en) | 2001-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| WO2003047519A3 (en) | 'compressed annular tablet with molded triturate tablet for oral and intraoral' | |
| AR020001A1 (es) | COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO | |
| WO2005046640A3 (en) | Multi-site drug delivery platform | |
| DE602004032149D1 (de) | Oros-push-stick für die kontrollierte abgabe von wirkstoffen | |
| MX2007015480A (es) | Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada. | |
| HUP0402154A2 (hu) | Metformint és glibenklamidot tartalmazó gyógyászati készítmény II-es típusú diabetes mellitus kezelésére | |
| WO2006072940A3 (en) | Controlled long acting release pharmaceutical preparation for use in the oral cavity | |
| BRPI0108435B8 (pt) | formulação e uso de entecavir de baixa dose | |
| RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
| IS7006A (is) | Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd | |
| AR045783A1 (es) | Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide | |
| AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
| WO2002011694A3 (en) | COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS | |
| ES2175663T3 (es) | Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis. | |
| RU2002122084A (ru) | Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных растройств | |
| AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
| CA2504872A1 (en) | Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections | |
| AR030551A1 (es) | Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante | |
| RU2005105302A (ru) | Композиция бицифадина | |
| UY26595A1 (es) | Formulaciones de entecavir de dosis bajas y uso | |
| CA2450915A1 (en) | Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure | |
| CA2727722A1 (en) | Use of dihydroimidazolones for the treatment of anxiety in dogs | |
| CA2457982A1 (en) | Use of nefiracetam for treating neurodegeneration | |
| CA2474430A1 (en) | A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |